Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations. Subjects will be seen on an every six week basis for 1 year or longer. Subjects who continue to receive Toca FC will receive the dose described in the "parent" protocol. If the Toca FC dose is adjusted for any reason, the serum concentration will be monitored. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scans will be performed as per standard of care.
If the subject has recurred/progressed, repeat intracranial injection of Toca 511 followed by Toca FC treatment may be offered to consenting patients.
Subjects who enter the study to continue Toca FC and subsequently discontinue Toca FC, and subjects who are only willing or able to perform limited testing will have viral testing alone, at the appropriate intervals.
After the first year, subjects will be seen twice yearly for the next 4 years and then contacted yearly for the next 10 years.
All subjects will be followed on study for at least 5 years regardless of whether they are taking Toca FC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Single arm Toca 511 vector/5-FC prodrug |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Toca 511 vector | Biological | Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector |
| Measure | Description | Time Frame |
|---|---|---|
| Long term safety follow up | This will be based on treatment emergent adverse events, clinical laboratory values and viral testing. | From study entry up to 15 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival in days from the initial Toca 511 administration on parent study to the date of death. | From initial Toca 511 administration to death of last patient alive for up to 15 years. |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival in days from the initial Toca 511 administration on parent study to confirmed disease progression or death from any cause. | from initial toca 511 administration to time of progression or death of any cause for up to 15 years. | |
| Objective response rate from initial dose of Toca FC from the parent protocol |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Asha Das, MD | Tocagen Inc. | Study Director |
| Michael Vogelbaum, MD, PhD, NS | The Cleveland Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | United States | ||
| UCSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine | Drug | Toca FC is an extended-release formulation of flucytosine. |
|
|
| Time from initial dose of Toca FC to death of last patient alive for up to 15 years. |
| San Diego |
| California |
| 92093 |
| United States |
| UCSF | San Francisco | California | 94143 | United States |
| Henry Ford Health System | Detroit | Michigan | 48202 | United States |
| JFK Medical Center Neuroscience Institute | Edison | New Jersey | 08820 | United States |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | United States |
| John Theurer Cancer Center at Hackensack University | Hackensack | New Jersey | 07601 | United States |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | United States |
| Ohio State University | Columbus | Ohio | 43210 | United States |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | United States |
| Swedish Neuroscience Institute | Seattle | Washington | 98122 | United States |
| ID | Term |
|---|---|
| D005909 | Glioblastoma |
| D001254 | Astrocytoma |
| D005910 | Glioma |
| D001932 | Brain Neoplasms |
| D009837 | Oligodendroglioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000630228 | vocimagene amiretrorepvec |
| D005437 | Flucytosine |
| ID | Term |
|---|---|
| D003596 | Cytosine |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided